UPPSALA, Sweden, January 13 /PRNewswire/ -- Beactica AB, the Swedish fragment-based drug discovery company, today announced a new research collaboration agreement with GE Healthcare (Chalfont St. Giles, UK), the world leading provider of molecular interaction analysis tools, and Uppsala University (Sweden). The collaboration combines Beactica's unique approach to fragment-based drug discovery and GE Healthcare's Biacore(TM) technology with enzymology expertise from Uppsala University.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090113/333930 )

Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore(TM) surface plasmon resonance instruments and applications for fragment-based drug discovery. The project also aims to identify novel high-quality leads against a clinically important, undisclosed protein target from Beactica's discovery pipeline. Financial terms of the agreement were not disclosed.

We look forward to deepening our relationship with GE Healthcare and Uppsala University, said Beactica's CEO, Dr Per Källblad. The Biacore technology is a core component of our kinetics-integrated lead discovery platform. Being an active part in the development of next - generation applications from GE Healthcare will enable us to stay at the forefront of our field.

About Beactica

Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. The company was spun out of Uppsala University in August 2006. As well as building collaborations with external companies, Beactica is progressing its own drug discovery programmes of small molecule therapeutics. For more information about Beactica, please visit http://www.beactica.com.

For further information, please contact Dr Per Källblad, CEO Beactica, +46(0)18-560880.

For further information, please contact Dr Per Källblad, CEO Beactica, +46(0)18-560880.